MigVax
Blood & Organ Banks · Israel · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Tarshish St, Qiryat Shmona, Hazafon, 110...Phone Number
+972 46953511Website
www.migvax.comRevenue
$13.8 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About MigVax
MigVax Ltd. is focused on developing an innovative oral subunit vaccine for COVID-19, known as MigVax-101, which utilizes a chimeric protein to elicit comprehensive immune responses. This vaccine aims to simplify administration by dissolving on the tongue, eliminating the need for healthcare professionals, and is stable at room temperature for two months. Targeting a wide range of clients, including pediatric, adolescent, and pregnant populations, MigVax addresses logistical challenges associated with current injectable vaccines. The company employs advanced analytical techniques, including an Artificial Neural Network, to predict future variants and enhance vaccine efficacy.Explore more
MigVax Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is MigVax your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at MigVax
Check out if MigVax is spiking on competitors!
Check if MigVax has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once MigVax has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Product Launch: Get notified when MigVax launches new products
Earning: See what the market has to say on MigVax recently announced quarterly report
MigVax, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Click to see if MigVax had a recent Job posting/layoffs
Recommended Actions
Reach out to Masked Content who joined MigVax as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
MigVax is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
MigVax is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about MigVax.
MigVax Tech Stack
A closer look at the technologies used by MigVax
See more technologies
Most Recent Scoops
Left Company
Executive Move
Ran Amir, Chief Executive Officer, has left the organization and now serves as Chief Executive Officer at Lehamim.
Lateral Move
Executive Move
New Hire
Executive Move
Ran Amir has assumed the role of Chief Executive Officer. Previously, Amir served as Chief Executive Officer at CannAssure Therapeutics.
New Hire
Executive Move
MigVax News & Media
MigVax Appoints Ran Amir As Its New CEO
QIRYAT SHMONA, ISRAEL, May 31, 2022 /EINPresswire.com/ -- MigVax Ltd., a start-up developing an oral subunit vaccine against COVID-19, today announced that it has appointed Ran Amir as its new CEO. David Zigdon, MigVax’s first CEO and CEO of the MIGAL …OurCrowd Portfolio Company MigVax: Tests Show Promising Results as COVID Vaccine Booster
OurCrowd portfolio company MigVax Ltd., a startup developing an oral subunit vaccine against COVID-19, has announced promising results from preclinical tests that demonstrated the effectiveness of its MigVax-101 booster for previously vaccinated persons. According to a note distributed by the company, tests carried out on... Read More The post OurCrowd Portfolio Company MigVax: Tests Show Promising Results as COVID Vaccine Booster appeared first on Crowdfund Insider.MigVax’s Subunit Oral COVID-19 Vaccine Preclinical Trial Demonstrates Effectivity as a Booster
QIRYAT SHMONA, Israel--(BUSINESS WIRE)--MigVax Ltd., a startup company developing an oral subunit vaccine against COVID-19, today announced promising results from preclinical tests that demonstrated the effectivity of its MigVax-101 subunit oral vaccine as a booster for previously vaccinated persons. In the trial, tests carried out on rats demonstrated that the MigVax-101 sub-unit oral vaccine, when administered in a boost format following an injected S1 protein, elicited markedly higher neutra
Read more news
Top Blood & Organ Banks Companies
See more top companies
Frequently Asked Questions Regarding MigVax
Sign Up For FreeTo access detailed company insights
MigVax Ltd. is focused on developing an innovative oral subunit vaccine for COVID-19, known as MigVax-101, which utilizes a chimeric protein to elicit comprehensive immune responses. This vaccine aims to simplify administration by dissolving on the tongue, eliminating the need for healthcare professionals, and is stable at room temperature for two... Read More
